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Abstract 
Triple negative breast cancer (TNBC), a special subset of breast cancer, refers to negative expressions 
of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth receptor 2 
(HER2). It is associated with extreme local recurrence and distant metastasis with highly invasive 
character. With advances in genomics, the bases of molecular classification of TNBC now include the 
heterogeneity of its expression at the molecular level and clinical pathology, apart from classical 
immunohistochemistry. Every subtype of TNBC has different individualized target drugs, which include 
epidermal growth factor receptor (EGFR) inhibitor, poly-AD-ribose polymerase (PARP) inhibitor, 
anthracycline or paclitaxel, immunotherapy and vascular endothelial growth factor receptor (VEGFR) 
inhibitor. Combinations of target drugs are also used. Thus, there are no widely recognized standards of 
genotype classification and individualized drug targeting in TNBC. In this review, relevant studies and 
latest developments on TNBC are presented. 
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Evidence has shown that breast cancer is widely 
considered as a leading cause of death among 
women, and it has been associated with 
significantly increasing morbidity in recent years 
[1]. In triple-negative breast cancer (TNBC), a 
subtype of breast cancer which is about 15 % of 
breast cancers, ERs, PR, and HER2 are not 
expressed [2,3]. Due to its poor prognosis, high 
local recurrence rate and distant metastasis, 
TNBC does not respond well to targeted 
therapies [4]. 
 
This disease is a highly heterogeneous tumor 
which has been classified into 6 subtypes 
according to histology and molecular biology 
characteristics; different molecular subtypes of 
TNBC have differences in clinical expressions, 
responses to treatment and prognosis [4-6]. 
Chemotherapy is currently a major systemic 
treatment scheme for TNBC. However, although 
cytotoxic chemotherapeutic agents for TNBC 
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patients are supposed to be the effective therapy 
option, some patients are inherently in sensitive 
to cytotoxic chemotherapy, while many patients 
have shown drug resistance, resulting in disease 
recurrence [7,8]. 
 
Previous reports indicated that in TNBC, the 
different expressions of genic subtypes produce 
different hereditary events. For example, 
mutations in RAD51D, MRE11 and PALB2 may 
confer a higher risk of TNBC in the subtypes [9]. 
Moreover, it has been reported that the high 
BRCA1 rs80350973 mutation associated with Ki-
67 indices might be a predictor of prognosis of 
TNBC [10]. Thus, these important genic 
hereditary events may provide critical guide for 
prediction of genic targeted therapies in TNBC.  
 
The rapid developments in investigative 
technologies of tissue chip and tissue 
microarrays have facilitated studies on genotype 
classifications in TNBC, resulting in enhanced 




AND THERAPEUTIC ADVANCES OF TNBC 
 
Genotype classification of triple-negative 
breast cancer 
 
In 2000, the utilization of tissue chip and 
microarrays from the report of Perou et al [11] led 
to the discovery of much greater differences in 
gene expressions between various breast 
cancers. On the basis of that finding, five basic 
subtypes of breast cancer were proposed, which 
include luminal A, luminal B, ERBB-2 (+), basal-
like and normal-like subtypes. A part of these 
subtypes pertains to triple-negative phenotype 
which was reported in 587 cases with TNBC by 
Lehmann et al [12]. Thus, the classification of 
TNBC was molecularly categorized as basal-like 
1 (BL1) with the genic characteristics of cell cycle 
and DNA damage response, and basal-like 2 
(BL2) subtypes with growth factor signaling and 
myo-epithelium marker; and immune-modulatory 
(IM) subtype. Others are mesenchymal (M) and 
mesenchymal stem-like (MSL) subtypes with 
expression of high differentiation and genes of 
growth factor pathways; and luminal androgen 
receptor (LAR) subtype activated by luminal 
signal [13]. 
 
Analysis of distinct molecular profiles by Burstein 
et al [14] identified the clinically-relevant TNBC 
subtypes as LAR, mesenchymal (MES), basal-
like immunosuppressed (BLIS), and basal-like 
immune-activated (BLIA), with each specific 
molecular target identified within the TNBC 
subtypes. Therefore, “triple-negative” is thought 
to refer to the common complexity of 
heterogeneous TNBC. Individualized drug 
targeting treatments related to heterogeneous 
TNBC and their clinical features are subjects of 
further studies. 
 
Individualized drug targeting in TNBC from 
genotype classification 
 
Due to lack of the expression of ER and HER2, 
TNBC is not sensitive to endocrine therapy and 
trastuzumab therapy. Thus, the patients have 
drug resistance, resulting in tumor recurrence, 
metastasis and poor prognosis. In addition, the 
signaling pathways, targets and molecular 
mechanisms of TNBC are too complex for easy 
development of individualized drug targeting. 
 
Poly ADP-ribose polymerase receptor 
inhibitor 
 
The members of poly ADP-ribose polymerase 
(PARP) PARP-1, PARP-2 and PARP-3 
participate in each step of DNA damage repair 
[15]. When PARP inhibitor affected on cancer 
cells with BRCA1/2 mutations, the inhibition of 
PARP activity can prevent the formation, thus, 
the dependent PARP of DNA damage repair 
recombination were not resolved, at last, the 
DNA single-strand break (SSB) without repair led 
to the DNA stalled replication forks to convert the 
DNA double-strand breaks (DSBs), causing the 
apoptosis because of the homologous 
recombination (HR) lacked of BRCA1/2, which 
was called the “PARP-BRCA synthetic lethality” 
[16]. Meanwhile, the theory uncovered the 
mechanisms of PARP inhibitors intermediates 
selectively killed the HR defective cells to provide 
the epidemiological evidences. 
Studies by Evans et al [17] found that patient-
derived xenografts (PDXs) harbored a 
heterogeneous set of genomic alterations 
consistent with the TNBC subtypes, which could 
capture the molecular and phenotypic 
heterogeneity of TNBC. 
 
Thus, beyond germline BRCA1/2, the PARP 
inhibitor could alter tumors and cause tumor 
regression in a variety of molecular subtypes in 
TNBC. Clinical trials by Lee et al [18] showed the 
phase I/Ib study of olaparib and carboplatin in 28 
women with TNBC. With olaparib 400mg 
bid+carboplatin AUC4 as the maximum tolerated 
dose, the complete response (CR) was one 
patient (69+ months), while the partial response 
(PR) was 5 patients (median 4 months, range: 4 - 
7 months).  
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The clinical trial revealed that the combination of 
olaparib and carboplatin had modest activity in 
sporadic TNBC patients. However, the study was 
at phase I/Ib, and the sample size was small. At 
present, there are a number of clinical 
experiments regarding combinations of PARP 
inhibitors with other chemotherapeutic drugs 
such as cisplatin, carboplatin and topotecans. 
The efficacy of combination treatment for BRCA-
related breast cancer has attained approximately 
70 %. However, the combination of olaparib and 





Generally, platinum drugs can directly impact on 
DNA synthesis through the crosslinking of DNA 
which limits DNA unwinding and replication, 
resulting in anti-cancer effects. Studies by 
Bignon et al [22] showed pCR group and non-
pCR patients with TNBC or deleterious BRCA1 
or BRCA2 mutation who received 
anthracycline/taxane-based neo-adjuvant 
chemotherapy had pathologic complete response 
(pCR). The pCR of BRCA1 and BRCA2 mutation 
carriers were 38.3 % [95 % CI, 26 %-55 %] and 
66 % respectively, and 42.6 % [95 % CI, 29.2 %-
56.8 %]. The disease-free survival (DFS) and 
overall survival (OS) in the pCR group were 
much better than those in the non-pCR group, 
indicating a high pCR rate after therapy in BRCA-
mutated TNBC which is of prognostic value. 
Failure of TNBC patients to reach effective pCR 
in neo-adjuvant chemotherapy means poor 
prognosis. This theory is of interest to 
researchers in the study of the benefits of 
platinum drugs in treating tumors. A clinical trial 
has studied the feasibility of using homologous 
recombination deficiency (HRD) score to predict 
response of TNBC patients to platinum-
containing neo-adjuvant chemotherapy drugs 
[23]. Indeed, the efficacy of platinum drug 
therapy for TNBC is currently at the clinical trial 
phases, with emphasis on neo-adjuvant 
chemotherapies and chemotherapies in 
advanced TNBC patients [24,25]. However, this 
does not involve the trial phases of assisted 
therapy for TNBC after operation, which requires 
a large number of clinical data for verification. 
 
Epidermal or vascular endothelial growth 
factor receptor inhibitors 
 
Epidermal growth factor receptor (EGFR) and 
vascular endothelial growth factor receptor 
(VEGFR) are both classic structures of receptor 
tyrosine kinase (RTK); the former inevitably 
induces tumor cell proliferation, invasion, 
metastasis and angiogenesis by activating Ras-
Raf-MAPK, JNK and PI3 pathways [26, 27]. 
Overexpression of VEGR also affects these 
processes. The major inhibitors of EGFR are 
RTK inhibitor and anti-EGFR monoclonal 
antibody (mAb). These inhibitors could be 
potential targets for TNBC therapy [28]. 
 
In trials conducted by Baselga et al [29], a group 
of 173 patients with TNBC were randomly given 
either cisplatin combined with cetuximab or 
cisplatin alone. Compared with cisplatin group, 
the overall response rate (ORR) of the cisplatin + 
cetuximab group increased from 10.3 % to 20 %. 
The median overall survival (OS) was in the 
range of 9.4 to 12.9 months, while the 
progression-free survival (PFS) increased from 
1.5 months to 3.7 months. This showed that the 
addition of cetuximab to cisplatin could double 
ORR and prolong PFS and OS of TNBC patients. 
The novel targeted drug apatinib is an oral 
VEGFR which has been shown to exhibit certain 
effectiveness against TNBC [30]. Multicenter 
phase II studies revealed that the recommended 
dose of 750 mg apatinib/day was better than 500 
mg/day with respect to controlling the disease 
and adverse events.  Research teams have 
examined VEGF-dependent biomarkers in 
patients using apatinib, to identify advanced 
breast cancer population sensitive to the drug 
[30,31]. 
 
Hepatocyte growth factor receptor inhibitor 
 
MET protein encoded by MET oncogene is a 
membrane-bound tyrosine kinase implicated in 
the formation and/or progression of TNBC. After 
activation by hepatocyte growth factor receptor 
(HGF), MET signaling pathway can induce the 
transformation of epithelia-mesenchymal 
transition (EMT) to augment cancer cell migration 
and invasion. Studies have confirmed that 
overexpression of c-Met can independently 
predict poor outcomes in breast cancer [32]. The 
progression of TNBC can be promoted by 
aberrant dysregulation of the receptor tyrosine 
kinase c-Met. A new report has shown that the 
common flavanol glycoside rutin is a potential 
lead molecule for preventing and controlling c-
Met-dependent breast malignancies [33]. 
Through bioassay-guided identification, rutin was 
found to inhibit breast cancer cell proliferation, 
migration and invasion. When rutin was injected 
into nude mouse at 30 mg/kg, 3 times/week, the 
growth of MDA-MB-231/GFP orthotopic 
xenograft was significantly reduced in TNBC [33]. 
 
PI3K/AKT/mTOR pathway inhibitor 
 
The viability, proliferation, amplification, 
migration, invasion and angiogenesis in several 
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physiological and pathological processes are 
induced and mediated by the PI3K/AKT/mTOR 
pathway. The PI3K/AKT/mTOR pathway is overly 
activated in TNBC [34]. In a recent phase I trial of 
mTOR inhibition at the University Texas MD 
Anderson Cancer Center [35], advanced TNBC 
patients were treated with rapamycin combined 
with liposomal doxorubicin and bevacizumab. 
The results showed objective RR of 21 %, 
complete response (CR) of 8 %, partial 
response of 13 %, and the data showed disease 
stability for at least 6 months in 19 % patients, a 
40 % clinical benefit rate, while 74 % of the 
patients had aberrant PI3K pathway.  
 
A randomized trial tested liposomal doxorubicin, 
bevacizumab, and temsirolimus (DAT) or 
liposomal doxorubicin, bevacizumab, and 
everolimus (DAE) to identify aberrations in PI3K 
pathway, with a view to improving the possibility 
of targeting the pathway to enhance 
chemotherapy response [35]. 
Rhizomaamorphophalli has also been shown to 
be a potential targeting therapeutic agent for 
TNBC [35]. Studies by Wu et al [36] found, 
through flow cytometry analysis that MDA-MB-
231 cells treated with RhA were arrested at the S 
phase, because RhA decreased the migration 
and invasion of MDA-MB-231 cells, so that 
PI3K/AKT/mTOR pathway was inhibited. This 
suggests that RhA is a potential therapeutic 
candidate in the treatment of TNBC through the 
inhibition of the PI3K/AKT/mTOR pathway. 
 
Androgen receptor inhibitor 
 
The androgen receptor (AR) accounts for 10 % 
of LAR subtypes of TNBC, which is driven by AR 
signal and is sensitive to AR retardants. In ER 
subtypes, ERα and ERβ are two particular 
receptors which are closely associated with 
aggressive phenotypes of breast cancer [37]. 
This novel study revealed that the TNBC cell line 
can express endogenous ERβ2 only, and that its 
expression increased in TNBC cells and 
decreased cell proliferation and invasion. The 
expression of ERβ2also decreased the 
expression of prolyl hydroxylase 3 (PHD3) gene 
and is linked to increased hypoxia inducible 
factor 1α (HIF-1α) protein. These findings 
elucidated the importance of ERβ2 in enhancing 
TNBC cell proliferation and invasion, and also 
revealed that modulation of ERβ and ERβ1 
signaling contributes to the invasive 
characteristics of TNBC [37]. Enzalutamide is a 
new-style anti-androgen drug. A well-designed 
multi-center Simon’s phase II clinical trial 
evaluated the efficacy of enzalutamide on AR-
positive TNBC, and found that clinical benefit 
rate (CR or PR or stable disease) was 42 % 
during a 16-week follow-up. The data showed 
that non-luminal AR subtype of TNBC had low 
level of AR expression, indicating that it benefited 
from the AR- targeted therapy [38]. 
 
Steroid hormones in the supernatant of MDA-
MB-453 and primary cancer-associated 
fibroblasts (CAFs) were used by Kikuchi et al to 
study the correlation between androgen synthetic 
enzymes and CAFs [39]. The results revealed 
that the expressions of 17βHSD2, 17βHSD5, and 
5α-reductase1 were increased by CAFs. In 
addition, 17βHSD2 and 17βHSD5 in IL-6 were 
partially dependent on phosphorylated STAT3, 
while the induction of HGF-mediated 5α-
reductase1 was linked to phosphorylated ERK, 
suggesting that intra-tumoral androgen 
metabolism in ER-negative breast cancer are 
regulated IL-6 and HGF. These findings are 





The genotype classification of TNBC is 
necessary for understanding the biological 
characteristics and clinical manifestation, and for 
developing individualized drug targeting for 
TNBC. Comprehensive clinical studies have 
shown that cytotoxic chemotherapy is the main 
therapeutic approach to TNBC. Indeed, PARP 
inhibitor and platinum drugs are very effective for 
treating TNBC with BRCA mutation. Researchers 
consider that these are not limited to this patient, 
gene homologous recombination is taken into 
consideration in the hope of development of 
clinical practices; It would be a significant 
hallmark to demonstrate effectiveness and 
tolerance of AR inhibitors, since AR is a 
molecular target with high positive expression in 
TNBC. In all, more clinical trials of subgroups in 
larger populations with heterogeneity of TNBC 
subtypes should be particularly focused on, so as 
to improve TNBC prognosis. Due to crosslinking 
of TNBC and signaling pathways, the application 
of different combinations of individualized drug 
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